Jun 9, 2020Paper

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

BioRxiv : the Preprint Server for Biology
Brandi N WilliamsonEmmie de Wit


Effective therapeutics to treat COVID-19 are urgently needed. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. Here, we tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection. To evaluate the effect of remdesivir treatment on SARS-CoV-2 disease outcome, we used the recently established rhesus macaque model of SARS-CoV-2 infection that results in transient lower respiratory tract disease. Two groups of six rhesus macaques were infected with SARS-CoV-2 and treated with intravenous remdesivir or an equal volume of vehicle solution once daily. Clinical, virological and histological parameters were assessed regularly during the study and at necropsy to determine treatment efficacy. In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs. Virus titers in bronchoalveolar lavages were significantly reduced as early as 12hrs after the first treatment was administered. At necropsy on day 7 after inoculation, lung viral loads of remdesivir-treated animals were significantly lower and there was a clear reduction in damage to the lung tissue. Therape...Continue Reading


Jun 24, 2020·Frontiers in Public Health·Raghuvir KeniKrishnadas Nandakumar
Jul 12, 2020·Infectious Diseases and Therapy·Matthew R DavisJason M Pogue
Sep 18, 2020·Forensic Sciences Research·Ricardo Jorge Dinis-Oliveira
Apr 24, 2020·BMJ : British Medical Journal·Robin E Ferner, Jeffrey K Aronson
Aug 25, 2020·Current Pharmacology Reports·Puja KumariLekha Saha
Aug 26, 2020·Der Radiologe·C Dodt, N Schneider
Sep 29, 2020·Frontiers in Immunology·Inmaculada Sanclemente-AlamanUlises Gómez-Pinedo
Sep 5, 2020·Indian Journal of Medical Microbiology·Jobin John JacobKarthik Gunasekaran
Jun 24, 2020·Khirurgiia·Sh V TimerbulatovV M Timerbulatov
Oct 8, 2020·Critical Care : the Official Journal of the Critical Care Forum·Salleh N EhaidebAbderrezak Bouchama
Oct 16, 2020·Clinical Microbiology Reviews·Jakob J MalinJan Rybniker
Nov 21, 2020·Expert Review of Respiratory Medicine·Atieh YaghoubiSaman Soleimanpour
Oct 30, 2020·Nature Reviews. Microbiology·Philip V'kovskiVolker Thiel
Feb 8, 2021·European Journal of Pharmacology·Afra RezagholizadehTaher Entezari-Maleki
Oct 27, 2020·Current Transplantation Reports·Justin C LaracyMarcus R Pereira
Dec 8, 2020·Virusdisease·Suresh KumarNagarajan Perumal
Feb 17, 2021·Indian Journal of Medical Microbiology·Jobin John JacobKarthik Gunasekaran
Feb 27, 2021·Expert Opinion on Pharmacotherapy·María Del Mar GutierrezPere Domingo
Feb 23, 2021·Frontiers in Molecular Biosciences·Rajashri R Naik, Ashok K Shakya
Mar 26, 2021·Frontiers in Molecular Biosciences·Karthik VivekanandhanMuthupandian Saravanan
May 8, 2021·Journal of Global Health·Yijia DongEvropi Theodoratou
Jun 29, 2021·Frontiers in Molecular Biosciences·Jeyanthi VenkadapathiSanthi Venkatapathy

❮ Previous
Next ❯

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

American Thoracic Society: Allergy, Immunology & Inflammation

This feed has been developed in conjunction with the American Thoracic Society for the benefit of its Allergy, Immunology, and Inflammation Assembly. It highlights new and impactful papers on allergy, asthma, genetics, and the pathogenesis of lung diseases.